Weekly Analysts’ Ratings Changes for Zura Bio (ZURA)

Zura Bio (NASDAQ: ZURA) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2024 – Zura Bio was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 11/4/2024 – Zura Bio is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $15.00 price target on the stock.
• 10/21/2024 – Zura Bio had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
• 10/18/2024 – Zura Bio had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 9/19/2024 – Zura Bio had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $4.30 on Thursday. The business has a 50 day simple moving average of $4.17 and a 200 day simple moving average of $4.09. Zura Bio Limited has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts expect that Zura Bio Limited will post -0.47 earnings per share for the current year.

Insiders Place Their Bets

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in shares of Zura Bio in the second quarter valued at approximately $43,000. Renaissance Technologies LLC lifted its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. SG Americas Securities LLC bought a new stake in Zura Bio during the third quarter valued at about $62,000. Forefront Analytics LLC grew its position in shares of Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after purchasing an additional 7,531 shares during the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in shares of Zura Bio in the third quarter worth about $156,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.